Evidence map›Paper›PMID 39131066›Full record

ReviewJournal of the Society for Cardiovascular Angiography & Interventions

Impact and Implications of Neurocognitive Dysfunction in the Management of Ischemic Heart Failure.

Daniela Tirziu, Michalina Kołodziejczak, Daniel Grubman, Carmen I Carrión, Lucas D Driskell, Yousif Ahmad, Mark C Petrie, Elmir Omerovic, Björn Redfors, Stephen Fremes and 2 more

Abstract readReview
In one paragraph

Review in Journal of the Society for Cardiovascular Angiography & Interventions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Daniela TirziuYale Cardiovascular Research Group, Yale School of Medicine, New Haven, Connecticut.
Michalina KołodziejczakYale Cardiovascular Research Group, Yale School of Medicine, New Haven, Connecticut.
Daniel GrubmanYale Cardiovascular Research Group, Yale School of Medicine, New Haven, Connecticut.
Carmen I CarriónDepartment of Neurology, Yale School of Medicine, New Haven, Connecticut.
Lucas D DriskellDepartment of Neurology, Yale School of Medicine, New Haven, Connecticut.
Yousif AhmadYale Cardiovascular Research Group, Yale School of Medicine, New Haven, Connecticut.
Mark C PetrieSchool of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
Elmir OmerovicDepartment of Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Björn RedforsDepartment of Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Stephen FremesSunnybrook Health Sciences Centre, Toronto, Canada.
Jeffrey N BrowndykeDepartment of Psychiatry & Behavioral Sciences, Division of Behavioral Medicine & Neurosciences, Duke University Medical Center, Durham, North Carolina.
Alexandra J LanskyYale Cardiovascular Research Group, Yale School of Medicine, New Haven, Connecticut.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurocognitive dysfunction is common in heart failure (HF), with 30% to 80% of patients experiencing some degree of deficits in one or more cognitive domains, including memory, attention, learning ability, executive function, and psychomotor speed. Although the mechanism is not fully understood, reduced cardiac output, comorbidities, chronic cerebral hypoperfusion, and cardioembolic brain injury leading to cerebral hypoxia and brain damage seem to trigger the neurocognitive dysfunction in HF. Cognitive impairment is independently associated with worse outcomes including mortality, rehospitalization, and reduced quality of life. Patients with poorer cognitive function are at an increased risk of severe disease as they tend to have greater difficulty complying with treatment requirements. Coronary revascularization in patients with ischemic HF has the potential to improve cardiovascular outcomes but risks worsening neurocognitive dysfunction even further. Revascularization by coronary artery bypass grafting carries inherent risks for delirium, cognitive impairment, neurologic injury, and stroke, which are known to exacerbate the risk of neurocognitive dysfunction. Alternatively, percutaneous coronary intervention, as a less-invasive approach, has the potential to minimize the risk of cognitive impairment but has not yet been evaluated as an alternative to coronary artery bypass grafting in patients with ischemic HF. Therefore, it is paramount to raise awareness of the neurocognitive consequences in ischemic HF and devise strategies for recognition and prevention as an important target of patient management and personalized decision making that contributes to patient outcomes.

Indexed as

cognitive impairmentcoronary artery bypass graftingcoronary revascularizationheart failureheart failure with reduced ejection fractionischemic heart failurepercutaneous coronary interventionvascular cognitive impairment

Identifiers

PMID39131066
PMCPMC11308118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.